GlassScriptPhysician profile
Peter J Laureijs
NPI 1831141043
$6,465.06
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $878 · 2021: $1,290 · 2022: $1,016 · 2023: $1,184 · 2024: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,657.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,004.14 | 2019-2024 | Prolia, Evenity, Repatha |
| Pfizer INC. | $976.46 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $589.91 | 2020-2024 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $548.50 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $349.66 | 2021-2024 | Jardiance, Emgality, Mounjaro |
| Glaxosmithkline, LLC. | $344.49 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $313.32 | 2019-2023 | Eliquis |
| Exact Sciences Corporation | $283.58 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $277.07 | 2019-2024 | |
| Abbvie INC. | $263.84 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $223.35 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $138.22 | 2019-2024 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $136.22 | 2019-2023 | Seglentis |
| Allergan, INC. | $109.30 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.77 | 2021-2024 | Jardiance, Tradjenta, Trijardy Xr |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $106.22 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $96.81 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.95 | 2021-2022 | |
| Dexcom, INC. | $68.86 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $64.77 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $60.28 | 2022-2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $58.99 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $42.77 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.59 | 2021-2023 | Trulance, Xifaxan |
| Abbott Laboratories | $31.46 | 2021-2024 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $26.61 | 2022-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $26.15 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $21.29 | 2024 | |
| Harmony Biosciences LLC | $18.61 | 2024 | |
| Alfasigma USA, INC. | $15.74 | 2020 | |
| Corcept Therapeutics | $14.47 | 2022 | |
| Amarin Pharma, INC. | $13.89 | 2020 | |
| Inogen, INC. | $12.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Laureijs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.